mouse vegf elisa kit picokine  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Boster Bio mouse vegf elisa kit picokine
    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in <t>VEGF-A</t> expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) <t>ELISA</t> analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
    Mouse Vegf Elisa Kit Picokine, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse vegf elisa kit picokine/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse vegf elisa kit picokine - by Bioz Stars, 2022-07
    94/100 stars

    Images

    1) Product Images from "Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury"

    Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury

    Journal: Theranostics

    doi: 10.7150/thno.64963

    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
    Figure Legend Snippet: Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P

    Techniques Used: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

    Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P
    Figure Legend Snippet: Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P

    Techniques Used: Irradiation, Enzyme-linked Immunosorbent Assay, Mouse Assay

    2) Product Images from "VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types"

    Article Title: VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types

    Journal: Experimental and Therapeutic Medicine

    doi: 10.3892/etm.2022.11176

    VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P
    Figure Legend Snippet: VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P

    Techniques Used: Over Expression, Mouse Assay, Marker, Injection, Fluorescence, Microscopy, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Activity Assay, Standard Deviation

    3) Product Images from "Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism"

    Article Title: Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism

    Journal: Theranostics

    doi: 10.7150/thno.18816

    Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .
    Figure Legend Snippet: Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .

    Techniques Used: Immunohistochemistry, Expressing, Mouse Assay, Infection, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Concentration Assay, Injection, Neutralization

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Boster Bio mouse vegf elisa kit picokine
    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in <t>VEGF-A</t> expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) <t>ELISA</t> analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P
    Mouse Vegf Elisa Kit Picokine, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse vegf elisa kit picokine/product/Boster Bio
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse vegf elisa kit picokine - by Bioz Stars, 2022-07
    94/100 stars
      Buy from Supplier

    Image Search Results


    Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P

    Journal: Theranostics

    Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury

    doi: 10.7150/thno.64963

    Figure Lengend Snippet: Activation of calcineurin/NFAT/HIF-1α signaling induces a Piezo1-mediated increase in VEGF-A expression in BMDMs. (A) RT-PCR analysis of HIF-1α mRNA levels in BMDMs 6 h after Yoda1 treatment (n = 3 independent experiments, Tukey test). (B) Western blot analysis of HIF-1α accumulation in BMDMs 24 h after Yoda1 treatment. Blots are representative of three independent experiments. (C) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with echinomycin (Ecn) for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (D) ELISA analysis of VEGF-A expression in BMDMs pretreated with Ecn for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (E) Western blot analysis of NFATC1 and NFATC3 in BMDMs treated with Yoda1 for 24 h. (F) Western blot analysis of HIF-1α in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (G) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with CsA or FK506 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (H) ELISA analysis of VEGF-A expression in BMDMs pretreated with CsA or FK506 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (I) Western blot analysis of NFATC1 and NFATC3 in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment. Blots are representative of three independent experiments. (J) RT-PCR analysis of VEGF-A mRNA levels in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 6-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). (K) ELISA analysis of VEGF-A expression in BMDMs pretreated with BAPTA-AM or GsMTx4 for 30 min before 24-h Yoda1 (5 μM) treatment (n = 3 independent experiments, Tukey test). Data are shown as mean ± SD. * P

    Article Snippet: Concentrations of VEGF-A were measured using the Mouse VEGF-A ELISA Kit (EK0541, Boster, China), according to the manufacturer's instructions.

    Techniques: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Enzyme-linked Immunosorbent Assay

    Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P

    Journal: Theranostics

    Article Title: Piezo1-mediated mechanosensation in bone marrow macrophages promotes vascular niche regeneration after irradiation injury

    doi: 10.7150/thno.64963

    Figure Lengend Snippet: Residual BM-Mφs upregulate VEGF-A after irradiation. (A) Quantification of bone marrow VEGF-A levels by ELISA at indicated times after 5-Gy irradiation and treatment with PBS-lip or Mφs depletion by Clo-lip (n = 4-5 mice). * P

    Article Snippet: Concentrations of VEGF-A were measured using the Mouse VEGF-A ELISA Kit (EK0541, Boster, China), according to the manufacturer's instructions.

    Techniques: Irradiation, Enzyme-linked Immunosorbent Assay, Mouse Assay

    VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P

    Journal: Experimental and Therapeutic Medicine

    Article Title: VEGF alleviates lower limb ischemia in diabetic mice by altering muscle fiber types

    doi: 10.3892/etm.2022.11176

    Figure Lengend Snippet: VEGF overexpression in gastrocnemius induces muscle fiber type switch in ischemic mice. (A) GFP marker levels 14 days after Ad-VEGF-GFP and Ad-GFP injection in skeletal muscle tissues were assessed by fluorescence microscopy. Scale bar=200 µm. (B) VEGF levels at 14 days as determined using ELISA. (C) Immunofluorescence staining of MHCIIa fibers (red) of ischemic gastrocnemius following treatment with Ad-VEGF-GFP or Ad-GFP. Scale Bars, 100 µm. (D) Citrate synthase activity in gastrocnemius. Data are presented as the mean ± standard deviation and are representative of 2 independent experiments. n=3 mice/group in each independent experiment. ** P

    Article Snippet: The supernatant was used to assay the concentration of VEGF (cat. no. EK0541; Boster Biological Technology) and enzyme activity of citric acid synthase (cat. no. MAK057; Sigma-Aldrich, Merck KGaA) according to manufacturer's protocols.

    Techniques: Over Expression, Mouse Assay, Marker, Injection, Fluorescence, Microscopy, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Activity Assay, Standard Deviation

    Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .

    Journal: Theranostics

    Article Title: Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism

    doi: 10.7150/thno.18816

    Figure Lengend Snippet: Triptolide and VNP20009 Synergistically Inhibit the Tumour Angiogenisis by Suppressing the Production of VEGF. A) Immunohistochemistry of CD31 + cells and VEGF expression in melanoma tumours from mice receiving triptolide and/or VNP20009 (VNP) treatments on d 7 post infection. CD31 + cells are indicated by red arrows. Bars on VEGF sections represent 10 μm . B) The quantification of CD31 + microvessels in tumours. Two sections per tumour were determined and four tumours were harvested in each group. The number of the CD31 + cells was calculated. Mean ± S.D., n=8 . C) VEGF expression in melanoma tumours was examined by RT-PCR. D) ELISA assays were performed to determine VEGF concentration in tumours. Mean ± S.D., n=4 . E) The treatment schedule of the combination therapy of VNP and VEGF neutralizing antibody, and its effect on the growth of tumours. The VEGF neutralizing antibody (10 μg / tumour) or the IgG control antibody (10 μg / tumour) were injected directly into the tumours three times on d 7, 9 and 10. VNP was intraperitoneally injected on d 8 post tumour inoculation. Mean ± S.D., n=5 . F) The bacterial colonization in the tumours was determined on d 5 post VNP infection in the VEGF neutralization assay. Mean ± S.D., n=5 .

    Article Snippet: For ELISA, tissue homogenates were subjected to the ELISA procedure as described by using the mouse VEGF ELISA kit (Boster, Wuhan, China).

    Techniques: Immunohistochemistry, Expressing, Mouse Assay, Infection, Reverse Transcription Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Concentration Assay, Injection, Neutralization